X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (230) 230
index medicus (194) 194
female (187) 187
male (187) 187
middle aged (186) 186
oncology (178) 178
aged (166) 166
adult (165) 165
chemotherapy (103) 103
cancer (97) 97
treatment outcome (76) 76
stomach neoplasms - drug therapy (69) 69
electricity (66) 66
antineoplastic agents - therapeutic use (61) 61
antineoplastic combined chemotherapy protocols - therapeutic use (61) 61
prognosis (60) 60
stomach cancer (59) 59
medicine & public health (57) 57
basic electric elements (55) 55
processes or means, e.g. batteries, for the direct conversionof chemical into electrical energy (54) 54
aged, 80 and over (53) 53
capecitabine (52) 52
disease-free survival (52) 52
stomach neoplasms - pathology (51) 51
gastric cancer (50) 50
care and treatment (49) 49
pharmacology & pharmacy (48) 48
cisplatin (46) 46
analysis (45) 45
fluorouracil (42) 42
metastasis (42) 42
cancer research (41) 41
retrospective studies (41) 41
survival (40) 40
therapy (40) 40
antineoplastic combined chemotherapy protocols - adverse effects (39) 39
tumors (39) 39
imatinib mesylate (37) 37
pharmacology/toxicology (37) 37
surgery (37) 37
antimitotic agents (36) 36
antineoplastic agents (36) 36
imatinib (36) 36
young adult (36) 36
drug therapy (35) 35
gastroenterology & hepatology (35) 35
survival rate (35) 35
5-fluorouracil (34) 34
gastrointestinal stromal tumors - drug therapy (34) 34
research (33) 33
clinical trials (32) 32
neoplasm staging (32) 32
trial (32) 32
survival analysis (31) 31
antineoplastic agents - adverse effects (30) 30
fluorouracil - administration & dosage (30) 30
physics (30) 30
carcinoma (29) 29
adenocarcinoma (28) 28
docetaxel (28) 28
drug administration schedule (28) 28
patients (28) 28
adenocarcinoma - drug therapy (27) 27
antineoplastic agents - administration & dosage (27) 27
diagnosis (27) 27
medical colleges (27) 27
mutation (27) 27
oxaliplatin (27) 27
supportive care (27) 27
calculating (26) 26
computing (26) 26
counting (26) 26
follow-up studies (26) 26
cisplatin - administration & dosage (25) 25
deoxycytidine - analogs & derivatives (25) 25
efficacy (25) 25
electric digital data processing (25) 25
liver neoplasms - drug therapy (25) 25
neoplasm metastasis (25) 25
adolescent (24) 24
antineoplastic combined chemotherapy protocols - administration & dosage (24) 24
fluorouracil - analogs & derivatives (24) 24
stomach neoplasms - mortality (24) 24
carcinoma, hepatocellular - drug therapy (23) 23
expression (23) 23
prospective studies (23) 23
combination (22) 22
mesylate (22) 22
time factors (22) 22
cancer therapies (21) 21
doxorubicin (21) 21
gastrointestinal stromal tumor (21) 21
gastrointestinal stromal tumors - pathology (21) 21
general tagging of cross-sectional technologies spanning over several sections of the ipc (21) 21
general tagging of new technological developments (21) 21
niacinamide - analogs & derivatives (21) 21
performing operations (21) 21
republic of korea (21) 21
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (21) 21
technologies or applications for mitigation or adaptation againstclimate change (21) 21
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drugs, ISSN 0012-6667, 2007, Volume 67, Issue 4, p. 612
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2018, Volume 29, Issue suppl_7
Journal Article
The Lancet, ISSN 0140-6736, 2013, Volume 381, Issue 9863, pp. 295 - 302
Background Until now, only imatinib and sunitinib have proven clinical benefi t in patients with gastrointestinal stromal tumours (GIST), but almost all... 
Journal Article
The Lancet, ISSN 0140-6736, 05/2019, Volume 393, Issue 10184, pp. 1914 - 1916
[...]less than half of the patients (46%) completed all the allocated cycles. [...]increasing the tolerability of the postoperative treatment by decreasing the... 
SURGERY | MEDICINE, GENERAL & INTERNAL | CHEMOTHERAPY | PHASE-III | Medical research | Microsatellites | Stability | Microsatellite instability | Regression analysis | Radiation therapy | Cancer therapies | Stomach cancer | Chemotherapy | Inhibitors | Mismatch repair | Gastric cancer | Cancer | Tumors | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10088, pp. 2492 - 2502
Summary Background For patients with advanced hepatocellular carcinoma, sorafenib is the only approved drug worldwide, and outcomes remain poor. We aimed to... 
Internal Medicine | CELL LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | IMMUNOTHERAPY | SORAFENIB | BLOCKADE | DOCETAXEL | PD-1 | Drug Administration Schedule | Humans | Antibodies, Monoclonal - adverse effects | Liver Neoplasms - drug therapy | Male | Response Evaluation Criteria in Solid Tumors | Treatment Outcome | Antineoplastic Agents - administration & dosage | Tumor Burden | Dose-Response Relationship, Drug | B7-H1 Antigen - metabolism | Carcinoma, Hepatocellular - drug therapy | Time Factors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Nivolumab | Carcinoma, Hepatocellular - pathology | Biomarkers, Tumor - metabolism | Female | Liver Neoplasms - pathology | Aged | Virus diseases | Medical colleges | Care and treatment | Cell death | College teachers | Hepatoma | Comparative analysis | Drug approval | Slopes | Therapy | Pemphigoid | Intravenous administration | Inhibitor drugs | PD-1 protein | Funding | Liver | Medical services | Clinical trials | Hepatocellular carcinoma | Lymphocytes T | Infections | Metastasis | Dosage | Cancer therapies | B7 antigen | Acceptability | Incidence | Hepatitis | Liver cancer | Pathways | Quality | Immunotherapy | Safety engineering | Safety management | Safety | Expansion | Drug dosages | Liver diseases | Effectiveness | Mortality | Group dynamics | Patients | Hospitals | Inhibitors | Immune checkpoint | Adults | Solid tumors | Hepatitis C virus | Hepatitis C | Tumors | Apoptosis
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 4/2017, Volume 35, Issue 2, pp. 180 - 188
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. 11537 - 11537
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2015, Volume 33, Issue 2, pp. 172 - 179
Purpose This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma... 
ANGIOGENESIS | ONCOLOGY | PATHWAY | SUNITINIB | ABT-869 | RISK | BRIVANIB | INHIBITOR | CANCER | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Hand-Foot Syndrome - etiology | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Liver Neoplasms - etiology | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Hypertension - chemically induced | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Liver Neoplasms - pathology | Carcinoma, Hepatocellular - etiology | Odds Ratio | Drug Administration Schedule | Risk Factors | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Niacinamide - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Sorafenib | Carcinoma, Hepatocellular - pathology | Aged | Indazoles - adverse effects | Indazoles - therapeutic use | Bone3 | ORIGINAL REPORTS | Bios3
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2019
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9742, pp. 687 - 697
Journal Article